Benzinga
Benzinga
Benzinga
mercoledì, settembre 30

Cadrenal Therapeutics Inc

CVKDNASDAQ
Trade with Public
Trade with Public
$1.09
-0.03-2.68%
In chiusura: Sep 28, 5:00 PM EST
$1.06
-0.06-5.36%
Pre-mercato: 5:30 AM EST
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoConfrontaRapporto azionario

Cadrenal Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Cadrenal Therapeutics (CVKD).

Price Target Range — 6 Quarters

Analyst Consensus — 2 Analysts

2Buy
Consensus RatingOutperform# Analysts2Avg. Consensus PT$37Upside to Avg. PT+3343.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →
DateFirmAnalystActionRating ChangePrice Target
Apr 7, 2026HC Wainwright & Co.Joseph PantginisPT CutBuy$32→$13
May 16, 2025HC Wainwright & Co.Joseph PantginisMaintainedBuy$32
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Watching Cadrenal Therapeutics; Zacks Small-Cap Research Gives Stock $17 Price Valuation

Benzinga Newsdesk

PRO
Watching Cadrenal Therapeutics; Zacks Small-Cap Research Gives Stock $25 Price Valuation

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Cadrenal Therapeutics, Lowers Price Target to $13

HC Wainwright & Co. analyst Joseph Pantginis maintains Cadrenal Therapeutics (NASDAQ:CVKD) with a Buy and lowers the price target from $32 to $13.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Cadrenal Therapeutics, Maintains $32 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Cadrenal Therapeutics (NASDAQ:CVKD) with a Buy and maintains $32 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Cadrenal Therapeutics, Adjusts Price Target To $32 (1-15 Reverse Stock Split)

HC Wainwright & Co. analyst Joseph Pantginis maintains Cadrenal Therapeutics (NASDAQ:CVKD) with a Buy, adjusts target to $32 from $3 (1-15 Reverse Stock Split).
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Cadrenal Therapeutics, Maintains $3 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Cadrenal Therapeutics (NASDAQ:CVKD) with a Buy and maintains $3 price target.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved